Screener
Rigel Pharmaceuticals RIGL Single reportable segment — Revenue recognized
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total Revenues | $58,818 | $53,333 |
| Less: | ||
| Employee related expenses | 21,002 | 19,538 |
| Commercial related expenses | 7,040 | 5,339 |
| Outside clinical trial related expenses | 6,927 | 4,371 |
| Cost of product sales | 4,606 | 4,409 |
| Consultants and third-party services | 4,006 | 3,409 |
| Other segment items | 3,352 | 3,494 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's single reportable segment — revenue recognized?
- Rigel Pharmaceuticals (RIGL) reported single reportable segment — revenue recognized of $58.82M in Q1 2026.
- What does single reportable segment — revenue recognized mean?
- Represents the total revenue generated by the company's primary operating segment from contracts with customers. This includes product sales, licensing fees, and milestone payments, reflecting the core commercial success of the firm's drug portfolio.
Ask your AI about Rigel Pharmaceuticals's single reportable segment — revenue recognized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude